The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-synculein Biology and Therapies, 2018Ordering the Earliest Neuronal Response Events to Native Alpha-synuclein Exposure
Study Rationale:
The protein alpha-synuclein forms aggregates in the brains of people with Parkinson’s. Here, we will not look at the end stage of protein aggregation and cell death, which has been... -
Alpha-synculein Biology and Therapies, 2018Structure and Function of Alpha-synuclein at the Pre-synapse
Study Rationale:
Current therapeutic strategies against synucleinopathies aim to either stabilize a native form of alpha-synuclein or to reduce its levels in patients. However, the normal... -
GBA Biology and Therapies, 2018Sphingolipid and Alpha-synuclein Interactions
Study Rationale:
In Parkinson’s, a normal cellular protein called alpha-synuclein begins to fold incorrectly (misfold), and this has a central role in the development of the disease. Our research... -
Alpha-synculein Biology and Therapies, 2018Effects of Post-translational Modifications on Alpha-synuclein Aggregation
Study Rationale:
Evidence suggests that the protein alpha-synuclein can cause the death of neurons in the brains of people with Parkinson’s disease (PD) by forming clusters (or aggregates) on the... -
GBA Biology and Therapies, 2018Molecular Imaging and Computer Typing in GBA-PD and Asymptomatic GBA-mutation Carriers
Study Rationale:
People who have a mutation in the GBA gene have a higher risk of developing Parkinson’s disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia... -
LRRK2 LEAPS, 2018Link between LRRK2, Alpha-synuclein and Lysosomal Function Supplement
Study Rationale:
Our goal is to test whether people with Parkinson’s disease (PD) who carry a LRRK2 mutation (compared to those carrying another genetic PD-predisposing mutation or people with...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.